Guidant assures FDA of pledge to quality control
This article was originally published in Clinica
Guidant underscored its commitment to enhancing its product quality systems in a recent letter to the US FDA, after concerns were raised by the agency following an inspection of the company's cardiac rhythm management (CRM) facility in September.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.